Brokers Offer Predictions for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Management boosted their FY2027 earnings estimates for shares of Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of $22.48 per share for the year, up from their prior estimate of $22.30. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Management also issued estimates for Intellia Therapeutics’ FY2028 earnings at $47.65 EPS and FY2029 earnings at $95.29 EPS.

NTLA has been the subject of a number of other reports. Wells Fargo & Company dropped their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday. Canaccord Genuity Group restated a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a report on Tuesday, November 19th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Monday. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday. Finally, Chardan Capital cut their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday. Two analysts have rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.12.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $9.45 on Monday. The company has a market capitalization of $962.47 million, a PE ratio of -1.74 and a beta of 1.80. Intellia Therapeutics has a fifty-two week low of $8.96 and a fifty-two week high of $33.28. The firm has a 50 day moving average price of $10.80 and a 200 day moving average price of $15.46.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 29,000 shares of company stock valued at $352,551 over the last 90 days. Insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after buying an additional 780,754 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Intellia Therapeutics by 125.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock valued at $1,411,000 after acquiring an additional 67,276 shares during the last quarter. Patient Square Capital LP acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at approximately $2,642,000. Charles Schwab Investment Management Inc. lifted its stake in Intellia Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock worth $17,006,000 after purchasing an additional 37,714 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in Intellia Therapeutics in the fourth quarter worth $421,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.